March 19, 2013 at 08:00 AM EDT
Antisense and TJAB Advance ATL1102 in MS
Antisense Therapeutics, an Australian biopharma, has contracted with Pharmaron to conduct a toxicology study of ATL1102 in multiple sclerosis (MS) patients. The company hopes to stage a China Phase IIb trial of the drug in China in partnership with Tianjin International Joint Academy of Biotechnology and Medicine (TJAB). The two entities extended the deadline for establishing a JV to develop ATL1102 until September 30, 2013, More details.... Stock Symbol: (ASX: ANP) Share this with colleagues: // //  
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here